Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Lecanemab Earns Priority Review Status in China: Eisai
March 1, 2023
- Japan Approves Pfizer’s Omicron-Tailored Vaccine for Ages 5-11
March 1, 2023
- Mitsubishi Chemical to Fix “Overextension” of Pharma Biz, Focus on 4 Therapeutic Areas, Japan/US: CEO
February 28, 2023
- Xocova Taken by Estimated 32,270 Patients as of Feb. 19: Shionogi
February 28, 2023
- Enhertu Approved in China for HER2 Positive Breast Cancer
February 28, 2023
- COVID-19 Drugs Haul Big Sales in 2022, Veklury Crosses 100 Billion Yen Line
February 27, 2023
- Pfizer Japan Files PARP Inhibitor Talazoparib for Breast and Prostate Cancer
February 27, 2023
- Astellas Presents Update on PI/II Study of AT845 for Late-Onset Pompe Disease
February 27, 2023
- Pfizer Japan Begins Amoxapine Recall, Ceases Shipments over Carcinogen Risks
February 27, 2023
- Ono Bags Right to Cue Biopharma’s Tregs-Inducing Bispecific Protein
February 24, 2023
- Shionogi’s Xocova Cuts Risks of Long COVID by 45%: Exploratory Data
February 24, 2023
- Opdivo Approved for NSCLC Neoadjuvant Use in Taiwan
February 24, 2023
- Teijin, Axcelead to Launch Drug Discovery Joint Venture
February 22, 2023
- Kidswell Bio Revs Up Biosimilar Push, G-Lasta, Eylea Follow-Ons in Development
February 22, 2023
- Pfizer Files RSV Vaccine in Japan
February 21, 2023
- FDA Target Date for Hot Flash Med Extended by 3 Months: Astellas
February 21, 2023
- Japan Approves Taisho’s Visceral Fat-Reducing Med as Nonprescription Drug
February 20, 2023
- US Patent Office Restarts PGR for Seagen Patent: Daiichi Sankyo
February 20, 2023
- PharmaEssentia Lays Out Sales Organization in Japan for 1st Product Launch
February 20, 2023
- Susmed Bags Japan Approval for Insomnia App
February 20, 2023
ページ
Japan is opening a new chapter in sleep medicine. The recent decision to allow medical institutions to advertise “sleep disorders”…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…